PERRIGO Co plc PRGO
Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.
Perrigo is a leading pure-play self-care company with more than a century of providing high-quality health and wellness solutions to meet the evolving needs of consumers. As one of the originators of the over-the-counter ("OTC") self-care market, Perrigo is led by its vision "To Provide The Best Self-Care For Everyone" and its purpose to "Make Lives Better Through Trusted Health and Wellness Solutions, Accessible To All".
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.25B | $4.37B | $4.66B | $4.45B | $4.14B | $4.09B | $3.87B | $4.73B | $4.95B | $5.28B |
| Cost of revenue | $2.76B | $2.83B | $2.98B | $3.00B | $2.72B | $2.59B | $2.44B | $2.90B | $2.97B | $3.23B |
| Gross profit | $1.49B | $1.54B | $1.68B | $1.46B | $1.42B | $1.49B | $1.43B | $1.83B | $1.98B | $2.05B |
| R&D | $95.4M | $112.2M | $122.5M | $123.1M | $122.0M | $121.7M | $119.2M | $218.6M | $167.7M | $184.0M |
| SG&A | $435.9M | $468.0M | $522.3M | $512.3M | $482.0M | $478.5M | $476.5M | $435.9M | $461.1M | $452.2M |
| Total operating expenses | $2.62B | $1.43B | $1.53B | $1.38B | $1.01B | $1.23B | $1.26B | $1.59B | $1.38B | $4.05B |
| Operating income | -$1.12B | $112.9M | $151.9M | $78.9M | $410.4M | $265.2M | $174.7M | $236.5M | $598.2M | -$2.00B |
| Interest expense | — | — | $173.8M | $156.0M | $125.0M | $127.7M | $117.5M | $128.0M | $168.1M | $216.6M |
| Pre-tax income | -$1.30B | -$80.7M | -$8.3M | -$139.1M | $258.7M | -$124.3M | $156.8M | $290.6M | $280.1M | -$4.85B |
| Income tax | $104.4M | $80.0M | $3.9M | $8.2M | $389.6M | $38.3M | $10.7M | $159.6M | $160.5M | $835.5M |
| Net income | -$1.43B | -$171.8M | -$12.7M | -$140.6M | -$68.9M | -$162.6M | $146.1M | $131.0M | $119.6M | -$4.01B |
| EPS, basic | -10.29 | -1.25 | -0.09 | -1.04 | -0.52 | -1.20 | 1.07 | 0.95 | 0.84 | -28.01 |
| EPS, diluted | -10.29 | -1.25 | -0.09 | -1.04 | -0.52 | -1.19 | 1.07 | 0.95 | 0.84 | -28.01 |
| Shares, diluted (wtd. avg.) | $138.5M | $137.4M | $135.3M | $134.5M | $133.6M | $137.2M | $136.5M | $138.3M | $142.6M | $143.3M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $531.6M | $558.8M | $751.3M | $600.7M | $1.86B | $631.5M | $344.5M | $541.9M | $678.7M | $622.3M |
| Receivables | $612.8M | $642.3M | $739.6M | $697.1M | $652.9M | $593.5M | $1.24B | $1.07B | $1.13B | $1.18B |
| Inventory | $1.15B | $1.08B | $1.14B | $1.15B | $1.02B | $1.06B | $967.3M | $878.0M | $806.9M | $795.0M |
| Total current assets | $2.80B | $2.48B | $2.83B | $2.72B | $3.86B | $3.13B | $2.73B | $2.90B | $2.82B | $2.81B |
| Property, plant and equipment | $898.7M | $917.8M | $916.4M | $926.3M | $864.1M | $864.6M | $774.2M | $829.1M | $833.1M | $870.1M |
| Goodwill | $2.05B | $3.32B | $3.53B | $3.49B | $3.00B | $3.10B | $3.10B | $3.98B | $4.18B | $4.05B |
| Other intangibles | $4.76B | $4.50B | $5.00B | $5.01B | $3.68B | $3.89B | $4.75B | $4.43B | $4.75B | $4.53B |
| Total assets | $8.54B | $9.65B | $10.81B | $11.02B | $10.43B | $11.49B | $11.30B | $10.98B | $11.63B | $13.87B |
| Accounts payable | $474.5M | $495.2M | $477.7M | $537.3M | $411.2M | $451.6M | $520.2M | $474.9M | $450.2M | $471.7M |
| Short-term debt | $36.6M | $36.4M | $440.6M | $36.2M | $603.8M | $37.3M | $3.4M | $190.2M | $70.4M | $572.8M |
| Total current liabilities | $1.01B | $1.04B | $1.59B | $1.11B | $1.59B | $1.38B | $1.34B | $1.54B | $1.44B | $1.84B |
| Long-term debt | $3.60B | $3.58B | $3.63B | $4.07B | $2.92B | $3.53B | $3.37B | $3.05B | $3.27B | $5.22B |
| Total liabilities | $5.60B | $5.33B | $6.04B | $6.18B | $5.27B | $5.83B | $5.50B | $5.32B | $5.46B | $7.91B |
| Retained earnings | -$3.68B | -$2.25B | -$2.08B | -$2.07B | -$1.93B | -$1.86B | -$1.70B | -$1.84B | -$1.98B | -$2.10B |
| Total equity | $2.94B | $4.32B | $4.77B | $4.84B | $5.15B | $5.66B | $5.80B | $5.67B | $6.17B | $5.96B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $238.5M | $362.9M | $405.5M | $307.3M | $156.3M | $636.2M | $387.8M | $593.0M | $698.9M | $654.9M |
| Depreciation and amortisation | $337.5M | $325.9M | $359.5M | $338.6M | $312.2M | $384.8M | $396.5M | $423.6M | $444.8M | $457.0M |
| Stock-based compensation | $54.6M | $64.4M | $68.8M | $54.9M | $60.1M | $58.5M | $52.2M | $37.7M | $43.8M | $23.0M |
| Capital expenditure | $93.4M | $118.3M | $101.7M | $96.4M | $152.1M | $170.4M | $137.7M | $102.6M | $88.6M | $106.2M |
| Investing cash flow | -$75.4M | $78.8M | -$77.5M | -$1.96B | $1.28B | -$187.8M | -$596.1M | -$126.8M | $2.34B | -$175.0M |
| Financing cash flow | -$220.5M | -$611.0M | -$187.2M | $421.6M | -$178.7M | -$181.1M | $1.8M | -$571.9M | -$3.00B | -$268.7M |
| Dividends paid | $159.3M | $152.5M | $149.7M | $142.4M | $129.6M | $123.9M | $112.4M | $104.9M | $91.1M | $83.2M |
| Buybacks | — | — | — | $0 | $0 | $164.2M | $0 | $400.0M | $191.5M | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001585364-26-000009.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |